Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 7, 2022, Orchard Therapeutics plc (the "Company") held its 2022 Annual General Meeting (the "Annual General Meeting"). At the Annual General Meeting, all the resolutions set out in the Notice of Annual General Meeting (the "Notice") sent to shareholders and filed in the Company's definitive proxy statement on Schedule 14A with the U.S. Securities and Exchange Commission on April 27, 2022 (the "Proxy Statement") were duly proposed and passed.

The matters presented for a vote, which are described in additional detail in the Notice and Proxy Statement, and the results of each resolution are listed below. Votes "Withheld" constitute abstentions.



     Ordinary Resolutions                           For        Against   Withheld
     To re-elect John T. Curnutte as a director     47,472,084 3,844,852 103,737
     To re-elect Bobby Gaspar as a director         50,230,816 1,088,511 101,346
     To re-elect Alicia Secor as a director         47,482,330 3,830,131 108,212
     To re-appoint PricewaterhouseCoopers LLP, a    51,039,963 353,125   27,585
     United Kingdom entity, as U.K. statutory
     auditors of the Company, to hold office until
     the conclusion of the next annual general
     meeting of shareholders
     To ratify the appointment of                   51,040,465 312,833   67,375
     PricewaterhouseCoopers LLP, a Delaware limited
     liability partnership, as the Company's
     independent registered public accounting firm,
     for the fiscal year ending December 31, 2022
     To authorize the Audit Committee to determine  50,975,749 297,941   146,983
     the Company's auditors' remuneration for the
     fiscal year ending December 31, 2022
     To receive the U.K. statutory annual accounts  50,936,554 403,178   80,941
     and reports for the fiscal year ended
     December 31, 2021 and to note that the
     Company's directors do not recommend the
     payment of any dividend for the year ended
     December 31, 2021
     To approve the compensation of the Company's   47,665,777 3,641,339 113,557
     named executive officers for the year ended
     December 31, 2021 on a non-binding, advisory
     basis
     To receive and approve the Company's U.K.      48,023,460 3,247,147 150,066
     statutory directors' remuneration report for
     the year ended December 31, 2021 on a
     non-binding, advisory basis
     To approve the Company's U.K. directors'       47,965,263 3,334,672 120,738
     remuneration policy

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.



Exhibit
Number                                     Description
104       Cover page interactive data file (embedded within the Inline XBRL document)

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses